Donnerstag, 24. Juni 2021
Navigation öffnen

Tissue Retractors for Radiation Therapy of Head and Neck Tumors



Juli 2020

Letztes Update:


Indikation (Clinical Trials):
Head and Neck Neoplasms


Erwachsene (18+)

Phase 2

University Hospital Heidelberg



Sebastian Adeberg, PD
Principal Investigator
University Hospital Heidelberg


Jürgen Debus, Prof.
Phone: +496221
Phone (ext.): 8021
» Kontaktdaten anzeigen
Adriane Hommertgen, Phd
Phone: +496221
Phone (ext.): 8021
» Kontaktdaten anzeigen

(1 von 1)

University Hopsital Heidelberg
69120 Heidelberg
GermanyRekrutierend» Google-Maps
Jürgen Debus, MD PhD
Phone: +49 6221 56
Phone (ext.): 34093
» Ansprechpartner anzeigen


Detailed Description:

The most effective approach to reducing acute toxicity after radiotherapy is to cut out healthy tissue from the radiation field. GWR can increase the distance between the tumor and normal tissue. Even the smallest geometric changes lead to a significant dose reduction in normal tissue and significant advantages for the patient. Adequate immobilization also reduces unwanted movements, especially of the tongue.

The GWR are manufactured as combinable modules according to the "modular principle". This improves reproducibility and flexibility and reduces development and manufacturing costs. The study is being conducted as a monocentric, prospective, randomized phase II study. A total of 34 patients who meet the inclusion criteria are examined for acute toxicity after radiotherapy of a malignant head and neck tumor. The primary goal of the study is to reduce acute toxicity through individual immobilization of the jaw and tongue. Secondary study goals are the evaluation of quality of life and long-term toxicity as well as local control and overall survival twelve months after radiotherapy. In both groups, radiation therapy is carried out in accordance with guidelines using image-guided radiotherapy.


Inclusion Criteria:

- Diagnosis of a malignant head and neck tumor

- Clinical target volume of radiotherapy may include portions of at least one region: oral cavity; Upper jaw; Lower jaw; Oropharynx; Hypopharynx; large salivary glands

- Indication for radiotherapy alone (postoperative or definitive)

- Age ≥ 18 years

- Karnofsky performance score ≥ 60

- Completed wound healing after tumor resection

- The patient's consent and written consent

- Ability of the patient to assess the nature and scope as well as possible consequences of the clinical study

- Adequate contraception in women of childbearing potential and in men

Exclusion Criteria:

- Pre-radiation in the head and neck area

- Multifocal, diffuse growing tumors

- Inadequate regression of toxicities from previous therapies

- Jaw clamp (cutting edge distance ≤ 2 cm)

- Simultaneous systemic tumor therapy during radiation (especially chemotherapy and immunotherapy)

- Indications that the participant is unlikely to adhere to the study protocol (e.g. lack of compliance)

- Missing written declaration of consent


Primary outcome:

1. Toxcicity (Time Frame - immediately after completin of Radiotherapy):
Number of grade III toxcicity events

Secondary outcome:

1. Assesment of Quality of life: questionnaire (Time Frame - up to 12 month after completion of radiotherapy):
Changes of Parameters on the Core Quality of Life Questionnaire C30, scores 1 to 6 (best)

2. Assesment of Quality of life: questionnaire (Time Frame - up to 12 month after completion of radiotherapy):
Changes of Parameters on the Core Quality of Life Questionnaire H&N35, scores 1 to 6 (best)


  • Experimental: Intervention
    Patient receive personalized 3D-printed GWR
  • Active Comparator: Control
    Patient receive standardized radiation protection tooth splints

Geprüfte Regime

  • tissue retractors:
    Patients receive a tissue retractor to spare healthy tissue during the course of radiation


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose